{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(12)"],"submitter":["Shi Y"],"pubmed_abstract":["<h4>Background</h4>Peripheral blood-based biomarkers (PBB) predicting response, survival and immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are still a matter of debate. Thus, we investigated the associations between PBB, the efficacy of ICIs and the incidence of irAEs.<h4>Methods</h4>Patients with advanced NSCLC, who had been treated at Peking Union Medical College Hospital and received ICIs or chemoimmunotherapy from January 2015 to December 2020, were retrospectively identified. PBBs results were retrieved from medical records. Associations with overall response rate, survival, and incidence of irAEs were assessed using Kruskal-Wallis, Kaplan-Meier analysis, Pearson's chi-squared and Stu"],"journal":["Translational lung cancer research"],"pagination":["4477-4493"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8743518"],"repository":["biostudies-literature"],"pubmed_title":["Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments."],"pmcid":["PMC8743518"],"pubmed_authors":["Liu J","Zhang D","Zhou Q","Chen M","Zhong W","Shi Y","Liu X","Wang M","Provencio M","Williams TM","Kocher F","Seeber A","Gao X","Zhao J","Jassem J","Yue Y","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.","description":"<h4>Background</h4>Peripheral blood-based biomarkers (PBB) predicting response, survival and immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are still a matter of debate. Thus, we investigated the associations between PBB, the efficacy of ICIs and the incidence of irAEs.<h4>Methods</h4>Patients with advanced NSCLC, who had been treated at Peking Union Medical College Hospital and received ICIs or chemoimmunotherapy from January 2015 to December 2020, were retrospectively identified. PBBs results were retrieved from medical records. Associations with overall response rate, survival, and incidence of irAEs were assessed using Kruskal-Wallis, Kaplan-Meier analysis, Pearson's chi-squared and Stu","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-19T02:47:56.326Z","creation":"2025-02-19T04:07:12.912Z"},"accession":"S-EPMC8743518","cross_references":{"pubmed":["35070755"],"doi":["10.21037/tlcr-21-710"]}}